Upon completion of this activity, participants should be able to: (1) Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference; (2) Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action; (3) Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy); and (4) Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/96330
- Start Date: 2024-12-20 06:00:00
- End Date: 2024-12-20 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 2.0 hours
AMA PRA Category 1 Credit™️: 2.0 hours
Nursing: 2.0 hours
Pharmacy: 2.0 hours - MOC Credit Details: ABIM - 2.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: BeiGene - Amount: 0.0 - Is Kind Support: False Source: Lilly (Any division) - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Community/Population Health, Learner Knowledge, Learner/Team Competence, Learner/Team Performance, Patient Health
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology